<< Common sense prevails as Brits say one dead swan is not a pandemic | Women can expect to outlive men >>
Read in | English | Español | 日本語 | 简体中文 | Finnish | Bahasa | Norsk

Fullerene shows promise in reducing radiation side effects

Published on April 11, 2006 at 3:05 AM · No Comments

Using transparent zebrafish embryos, researchers at Jefferson Medical College in Philadelphia have shown that a microscopic nanoparticle can help fend off damage to normal tissue from radiation.

The nanoparticle, a soccer ball-shaped, hollow, carbon-based structure known as a fullerene, acts like an "oxygen sink," binding to dangerous oxygen radicals produced by radiation.

The scientists, led by Adam P. Dicker, M.D., Ph.D., and Ulrich Rodeck, M.D., see fullerenes as a potentially "new class of radioprotective agents." Dr. Dicker, recently appointed Vice-Chair for Translational Research of the Radiation Therapy Oncology Group, is associate professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University and at the Kimmel Cancer Center at Jefferson. Dr. Rodeck is professor of dermatology at Jefferson Medical College.

While chemotherapy and radiotherapy are the standard treatments for cancer, they take their respective toll on the body. Radiation can damage epithelial cells and lead to permanent hair loss, among other effects, and certain types of systemic chemotherapy can produce hearing loss and damage to a number of organs, including the heart and kidneys. Some other side effects include esophagitis, diarrhea, and mouth and intestinal ulcers.

To date, only one drug, Amifostine, has been approved by the federal Food and Drug Administration, to help protect normal tissue from the side effects of chemotherapy and radiation. Researchers would like to develop new and improved agents.

Dr. Dicker, director of the Division of Experimental Radiation Oncology at Jefferson Medical College, and his group were exploring the molecular mechanisms responsible for cellular damage from radiation. They collaborated with a Houston-based drug company, C Sixty, and studied its radiation-protective agent, CD60_DF1.

To test how well it worked, they turned to tiny zebrafish embryos, which are transparent for the first month of life and allow scientists to observe closely organ damage produced by cancer treatments. Zebrafish have most of their organs formed by the third day after fertilization.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading